Role of tumour markers, cytogenetics

Annals of Oncology

Volumn 10, Issue SUPPL. 4, 1999, Pages

  Lamerz, Rolf ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Biliopancreatic cancer; CA 19 9; CA242; CAM 17.1; DPC4; K ras; p16; p53; Tumor markers

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CA 19-9 ANTIGEN; CA 195 ANTIGEN; CA 242 ANTIGEN; CA 50 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR; GLYCOLIPID; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; HAPTEN; KERATINOCYTE GROWTH FACTOR; MONOSIALOGANGLIOSIDE; PROTEIN P53; SIALIC ACID DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BREAST CANCER; CANCER SURVIVAL; COLORECTAL CANCER; CONFERENCE PAPER; CYTOGENETICS; DIGESTIVE SYSTEM CANCER; GENE MUTATION; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; ONCOGENE K RAS; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; UTERUS CANCER;

EID: 0032783998     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_4.S145     Document Type: Conference Paper

References (53)

1. Lamerz R. General laboratory tests and tumour markers in exocrine pancreatic cancer. Diagn Oncol 1993;3:146-57.
2. Plebani M, Basso D, Panozzo MP et al. Tumour markers in the diagnosis, monitoring and therapy of pancreatic cancer: state of the art. Int J Biol Markers 1995;10:189-99.
3. Lamerz R. CA 19-9, GICA (gastrointestinal cancer antigen). In L Thomas (ed.) Clinical laboratory diagnostics, TH-Books, Verlags-Ges, mbH, Frankfurt/Main, 1998, ch. 34.3, pp. 946-9.
4. Orntoft TF, Vestergaard EM, Holmes E et al. Influence of Lewis à(1,3/1,4)-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping and circulating tumor marker sialyl-Lewis a levels. J Biol Chem 1997;271:32260-8.
5. Maestranzi S, Przemioslo R, Mitchell H et al. The effect of benign and malignant liver disease on the tumor markers CA 19-9 and CEA. Ann Clin Biochem 1998;35:99-103.
6. Del Maschio A, Vanzulli A, Sironi S et al. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy. Radiology 1991;178:95-9.
7. Safi F, Schlosser W, Falkenreck S et al. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepato-Gastroenterology 1998;45:253-9.
8. Gattani AM, Mandeli J, Bruckner HW. Tumor markers in patients with pancreatic carcinoma. Cancer 1996;78:57-62.
9. Gogas H, Lofts FJ, Evans TRJ et al. Are serial measurements of CA 19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer 1998;77:325-8.
10. Ishii H, Okada S, Sato T et al. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepato-Gastroenterology 1997;44:279-83.
11. Okusaka T, Okada S. Sato T et al. Tumour markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Hepato-Gastroenterology 1998;45:867-72.
12. Rye PD, Bovin NV, Vlasova EV et al. Summary report on the ISOBM TD-6 workshop: analysis of 20 monoclonal antibodies against sialyl Lewis a and related antigens. Tumour Biol 1998;19:390-420.
13. Kawa S, Tokoo M, Hasebe O et al. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer 1994;70:481-6.
14. Haglund C, Lundin J, Kuusela P et al. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer 1994;70:487-92.
15. Lundin J, Roberts PJ, Kuusela P et al. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9. Anticancer Res 1995;15:2181-6.
16. Gansauge F, Gansauge S, Parker N et al. CAM 17.1 - a new diagnostic marker in pancreatic cancer. Br J Cancer 1996;74:1997-2002.
17. Yiannakaou JY, Newland P, Calder F et al. Prospective study of CAM 17-1/WGA mucin assay for serological diagnosis of pancreatic cancer. Lancet 1997;349:389-92.
18. Nichols JC, Gores GJ, LaRusso NF et al. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clinic Proc 1993;68:874-9.
19. Ramage JK, Donaghy A, Farrant JM et al. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterol 1995;108:865-9.
20. Strom BL, Maislin G, West SL et al. Serum CEA and CA 19-9: Potential future diagnostic or screening tests for gallbladder cancer?. Int J Cancer 1990; 45:821-4.
21. Paganuzzi M, Onetto M, Marroni P et al. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988; 61:2100-28.
22. Harmenberg U, Wahren B, Wiechel KL. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract. Cancer Res 1988; 48:1985-8.
23. Ker CG, Chen JS, Lee KT et al. Assessment of serum and bile levels of CA 19-9 and CA 125 in cholangitis and bile duct carcinoma. J Gastroent Hepatol 1991; 6:505-8.
24. Yeo CJ. Pancreatic cancer: 1998 Update. J Am Coll Surg 1998;187:429-42.
25. Hruban RH, Petersen GM, Ha PK et al. Genetics of pancreatic cancer: From genes to families. Surg Oncol Clin North Am 1998;7:1-23.
26. Rozenblum E, Schutte M, Goggins M et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4.
27. Schutte M, Hruban RH, Geradts J et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997;57:3126-30.
28. Wilentz RE, Gerardts J, Maynard R et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: Loss of intranuclear expression. Cancer Res 1998;58:4740-4.
29. DiGiuseppe JA, Hruban RH, Goodman SN et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994;101:684-8.
30. Redston MS, Caldas C, Seymour A et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-33.
31. Casey G, Yamanaka Y, Friess H et al. p53 mutations are common in pancreatic-cancer and absent in chronic pancreatitis. Cancer Lett 1993;69:151-60.
32. Yokoyama Y, Yamanaka Y, Friess H et al. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 1994;14:2477-84.
33. Laurent-Puig P, Lubin R, Semhoun-Ducloux S et al. Antibodies against p53 protein in the serum of patients with benign or malignant and biliary diseases. Gut 1995;36:455-8.
34. Suwa H, Ohshio G, Okada N et al. Clinical significance of serum p53 antigen in patients with pancreatic carcinoma. Gut 1997;40:647-53.
35. Hahn SA, Schutte M, Hoque ATMS et al. DPC4, A candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
36. Fukushige S, Furukawa T, Satoh K et al. Loss of chromosome 18q is an early event in pancreatic ductal tumorigenesis. Cancer Res 1998;58:4222-6.
37. Goggins M, Schutte M, Lu J et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-4.
38. Hruban RH, van Mansfeld ADM, Offerhaus GJA et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143:545-54.
39. Lemoine NR, Jain S, Hughes CM et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastro-enterology 1992;104:230-6.
40. Tada M, Ohashi M, Shiratori Y et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 1996;110:227-31.
41. Sturm PDJ, Hruban RH, Ramsoekh TB et al. The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol 1998;186:247-53.
42. Tada M, Teratani T, Komatsu Y et al. Quantitative analysis of K-ras gene mutation in pancreatic juice for diagnosis of pancreatic adenocarcinoma. Dig Dis Sci 1998;43:15-20.
43. Kondo H, Sugano K, Fukayama N et al. Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas. Cancer 1997;79:900-5.
44. Wilentz RE, Chung CH, Sturm PDJ et al. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 1998;82:96-103.
45. Abbruzzese JL, Evans DB, Raijman I et al. Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer. Anticancer Res 1997;17:795-801.
46. Caldas C, Hahn SA, Hruban RH et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-73.
47. Yamada T, Nakamori S, Ohzato H et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: Correlation with clinicopathological features. Clin Cancer Res 1998;4:1527-32.
48. Goggins M, Offerhaus GJA, Hilgers W et al. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology: Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 1998;152:1501-7.
49. DiGiuseppe JA, Hruban RH, Offerhaus GJA et al. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 1994;144:889-95.
50. Hruban RH, Sturm PDJ, Slebors RJC et al. Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients. Am J Pathol 1997;151:943-9.
51. Moskaluk CA, Hruban RH, Lietman A et al. Low prevalence of p16INK4a and CDK4 mutations in familial pancreatic carcinoma. Hum Mutat (In press).
52. Whitcomb DC, Preston RA, Aston CE et al. A gene for hereditary pancreatitis maps to chromosome 7q35. Gastroenterology 1996;110:1975-80.
53. Friess H, Kleef J, Gumbs A et al. Molecular versus conventional markers in pancreatic cancer. Digestion 1997;58:557-63.